Skip to main content

Table 6 Category of afatinib dose reduction

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Variables All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
Dose reduction events 39 (22%) 8 (8%) 31 (40%) < 0.0001
Category of afatinib dose reduction
 No change 140 (78%) 94 (92%) 46 (60%)  
 40 mg taper down to 30 mg 22 (12%)   22 (29%)  
 40 mg taper down to 20 mg 7 (4%)   7 (9%)  
 40 mg taper down to 0 mg 2 (1%)   2 (3%)  
 30 mg taper down to 20 mg 1 (1%) 1 (1%)   
 30 mg taper down to 15 mg 5 (3%) 5 (5%)   
 30 mg taper down to 0 mg 2 (1%) 2 (2%)